facturers, packers, or distributors, and original identifying lot or control numbers.

LIBELED: 9–5–61, Dist. Md.

CHARGE: 502(a)—while held for sale, the words "Professional Sample Not To Be Sold," "Physician Sample," "Complimentary Package," "Sample Not For Sale," "Physician Sample Not To Be Sold," and similar wording on the labels of a number of the articles, were false and misleading as applied to the articles then in possession of a repacker and intended for sale, and not then intended for use as "complimentary–not for sale" samples for physicians and others lawfully engaged in dispensing prescription drugs; 502(b)(1)—a number of the articles failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor; and 502(f)(1)—the labels of a number of the articles failed to bear adequate directions for use and they were not exempt from that requirement since they were drugs subject to the provisions of 503(b)(1) and their labels failed to bear an identifying lot or control number from which it was possible to determine the complete manufacturing history of the packages of the drugs as required by regulations.

DISPOSITION: 10–3–61. Default—destruction.

6708. Neo-Cough cough syrup. (F.D.C. No. 45954. S. No. 79–514 R.)

QUANTITY: 37 cases, each containing 36 3-oz. btls., at Arlington, Va.

SHIPPED: 10–27–59 and 1–3–61, from Philadelphia, Pa., by Hance Bros. & White.

LABEL IN PART: (Btl.) "Neo-Cough Cough Syrup For Children * * * Distributors Arlco Drug Co. * * * Each Fluid ounce Contains: * * * d-Methorphan H. Br. 15 mg. * * * Phenylephrine HCl. 15 mg. * * * Directions: Infants, from 3 months to 1 year, 10 to 15 drops."

LIBELED: 6–19–61, E. Dist. Va.

CHARGE: 502(f)(2)—when shipped, the labeling failed to bear adequate warnings against its use by individuals with high blood pressure, heart disease, diabetes, or thyroid disease; to keep it out of the reach of children; against its administration to children under 2 years of age; against its use by persons with a high fever or persistent cough; and that a persistent cough may indicate the presence of a serious condition.

The libel alleged also that other articles were adulterated under the provisions of the Act relating to foods, as reported in notices of judgment on foods.

DISPOSITION: 7–6–61. Consent—claimed by Arlco Drug Co., Arlington, Va., and relabeled.

6709. Adolphus Massagerizer and Wahl Powersage Electric Vibrator. (F.D.C. No. 46078. S. Nos. 84–595/6 R.)

QUANTITY: 11 Massagerizer devices and 11 vibrator devices at New York, N.Y., in possession of Adolphus Hohensee.

SHIPPED: Prior to 6–28–61, from outside the State of New York.

RESULTS OF INVESTIGATION: Examination showed that the Massagerizer was a vibrating pillow-like box having 2 metal ends, the other 4 sides being padded and covered with a pink rubberized material; and that one end had an adjustable knob-switch to turn the device on and adjust its speed of vibration.

Examination showed that the Powersage Vibrator was an electric hand massager, having 2 elastic metal bands that attached the device to the back of the hand thus leaving the palm free to massage where desired.

LIBELED: 7–13–61, S. Dist. N.Y.

CHARGE: 502(f)(1)—while held for sale, the labeling of the articles failed to bear adequate directions for use as a treatment for and preventive of migraine headache, impaired hearing, prostate gland trouble, internal cancer, tumors, receding gums, poor vision, poor digestion, varicose veins, and hardening of the arteries; and to clear sinuses; remove wrinkles; rejuvenate personality glands; remove cobwebs from the brain; and for spot reducing, which were the diseases, conditions, and purposes for which the articles were recommended in oral statements made by Adolphus Hohensee during the course of 3 lectures given at New York, N.Y., on or about June 28 and 29, 1961.

DISPOSITION: 8–22–61. Default—delivered to the Food and Drug Administration.

DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS

DRUGS FOR HUMAN USE

6710. Sal-Amino C tablets. (F.D.C. No. 45745. S. No. 62–717 R.)

QUANTITY: 95 100-tablet btls. and 149 1,000-tablet btls. at Columbus, Ohio, in possession of Columbus Hospital Supply Co.

SHIPPED: In March or April 1953, from Philadelphia, Pa.

LABEL IN PART: (Btl.) "List No. 2083 Sal-Amino C Tablets Control No. 9431 Distributed by Columbus Hospital Supply Company Columbus 15, Ohio Caution: * * * Each tablet Represents: Sodium Salicylate (3 gr.) 200.0 mg. Calcium Succinate (2 gr.) 133.3 mg. Para Aminobenzoic Acid (1 gr.) 66.7 mg. Vitamin C (0.3 gr.) 20.0 mg."

RESULTS OF INVESTIGATION: Examination showed that the article contained 47 percent of the declared amount of ascorbic acid (vitamin C) and 75 percent of the declared amount of para-aminobenzoic acid.

LIBELED: 4–26–61, S. Dist. Ohio.

CHARGE: 501(c)—while held for sale, the strength of the article differed from and its quality fell below that which it purported or was represented to possess; and 502(a)—the label statements "Each Tablet Represents: * * * Para Aminobenzoic Acid (1 gr.) 66.7 mg. Vitamin C (0.3 gr.) 20.0 mg." were false and misleading as applied to an article that contained less than the declared amounts of these ingredients.

DISPOSITION: 6–16–61. Default—destruction.

6711. Secobarbital sodium capsules. (F.D.C. No. 46140. S. No. 97–334 R.)

QUANTITY: 1 100-capsule btl., 12 500-capsule btls., and 45 1,000-capsule btls., at Buffalo, N.Y.

SHIPPED: From Philadelphia, Pa., by Richlyn Laboratories.

LABEL IN PART: (Btl.) "No. 4090 * * * Secobarbital Sodium * * * 1½ Grain * * * Distributed by Direct Laboratories, Inc., Buffalo 4, New York, Control 9228."

RESULTS OF INVESTIGATION: The article was repacked and labeled by the dealer after its shipment in bulk as described above. Analysis showed that the article failed to meet the United States Pharmacopeia requirement for *secobarbital sodium capsules* in that its weight variation was not in accordance with the Pharmacopeia.